References
- Marshall C J. RAS effectors. Curr Opin Cell Biol 1996; 8: 197–204
- Rubio I, Downward J. RAS activation revisited. Signal Transduction 2001; 1(Suppl. 1)11–24
- Giehl K. Oncogenic RAS in tumor progression and metastasis. Biol Chem 2000; 386: 193–205
- Neubauer A, Dodge R K, George S L, Davey F R, Silver R T, Schiffer C A, et al. Prognostic importance of mutations in the RAS proto-oncogenes in de novo acute myeloid leukemia. Blood 1994; 83: 1603–1611
- Wittinghofer A. Signal transduction via RAS. Biol Chem 1998; 379: 933–937
- Gilliland D G. Haematologic malignancies. Curr Opin Haematol 2001; 8: 189–191
- Reilly J T. Pathogenesis of acute myeloid leukemia and inv(16) (p13;q22): a paradigm for understanding leukaemogenesis?. Br J Haematol 2004; 128: 18–34
- MacKenzie K L, Dolnikov A, Millington M, Shounan Y, Symonds G. Mutant N-ras induces myeloproliferative disorders and apoptosis in bone marrow repopulated mice. Blood 1999; 93: 2043–2056
- Jücker M, Abts H, Li W, Schindler R, Merz H, Günther A, et al. Expression of Interleukin-6 receptor in Hodgkins's disease. Blood 1991; 77: 2413–2418
- Jücker M, Feldman R A. Identification of a new adaptor protein that may link the common ß subunit of the receptor for granulocyte/macrophage colony-stimulating factor, Interleukin (IL)- 3, and IL-5 to phosphatidylinositol 3-kinase. J Biol Chem 1995; 270: 27817–27822
- Kitamura T, Tange T, Terasawa T, Chiba S, Kuwaki T, Miyagawa K, et al. Establishment and characterization of a unique human cell line that proliferates dependently on GM-CSF, IL-3, or erythropoietin. J Cell Physiol 1989; 140: 323–334
- Birkenkamp K U, Geugien M, Schepers H, Westra J, Lemmink H H, Vallenga E. Constitutive NF-kB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway. Leukemia 2004; 18: 103–112
- Taylor S J, Resnick R J, Shalloway D. Non-radioactive determination of RAS-GTP levels using activated RAS interaction assay. Methods Enzymol 2001; 333: 333–342
- Giehl K, Skripczynski B, Mansardi A, Menke A, Gierschik P. Growth factor-independent activation of the RAS-RAF-MEK-MAPK pathway in the human pancreatic carcinoma cell line PANC-1 carrying activated K-RAS: implication for cell proliferation and cell migration. Oncogene 2000; 19: 2930–2942
- de Rooij J, Bos J L. Minimal RAS-binding domain of Raf1 can be used as an activation-specific probe for RAS. Oncogene 1997; 14: 623–625
- Herrmann C, Martin G A, Wittinghofer A. Quantitative analysis of the complex between p21RAS and the RAS-binding domain of the human Raf-1 protein kinase. J Biolog Chem 1995; 270: 2901–2905
- Idia M, Towatori M, Nakao A, Iida H, Kiyoi H, Nakano Y, et al. Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation. Leukemia 1999; 13: 585–589
- Gilliland D G, Griffin J D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532–1542
- von Bergh A RM, Wijers P M, Groot A J, van Zelderen-Bhola S, Falkenburg J HF, Kluin P M, Schuuring E. Identification of a novel RAS GTPase-activating protein (RASGAP) gene at 9q34 as an MLL fusion partner in a patient with de novo acute myeloid leukemia. Genes Chromosomes Cancer 2004; 39: 324–334
- Nakagawa T, Saitoh S, Imoto S, Itoh M, Tsutsumi M, Hikiji K, et al. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992; 49: 114–122
- Reuter C WM, Morgan M A, Bergmann L. Targeting the RAS signaling pathway: a rational, mechanism-based treatment for hematologic malignancies. Blood 2000; 96: 1655–1669
- Lancet J E, Karp J E. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 2003; 102: 3880–3889